Leuprolide acetate is under clinical development by Livzon Pharmaceutical Group and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Leuprolide acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Leuprolide acetate overview

Leuprolide acetate is under development for the treatment of endometriosis, prostate cancer, premenopausal breast cancer and fibroid. The therapeutic candidate is administered through subcutaneous route. It is formulated in the form of microspheres. It acts by targeting the gonadotropin-releasing hormone receptor (GnRH).

Livzon Pharmaceutical Group overview

Livzon Pharmaceutical Group (Livzon) a subsidiary of Joincare Pharmaceutical Group Industry Co Ltd, is a pharmaceutical company which is engaged in developing, manufacturing and distributing pharmaceutical products. The company provides preparation drug products, bulk medicines and intermediates, and diagnostic reagents and equipment. Its products include menotropins injection, urofollitropin injection, perospirone hydrochloride tablets, and ranitidine bismuth citrate tablets, among others. Livzon offers diagnostic kits such as BV quick-test kit, anti-HCV rapid test, diagnostic kits, anti-HAV IgM ELISA kit, anti-TOXO IgG ELISA and HBsAg ELISA kit. The company offers drugs for various therapeutic areas such as antibiotics, antibacterial, gastrointestinal, psychotropic, antiviral, immunomodulation, anti-allergic and traditional Chinese medicine. It operates through its production facility located in Shanxi, Gansu and Yunan, China. Livzon is headquartered in Zhuhai, China.

For a complete picture of Leuprolide acetate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.